Lipid Insights

The 2026 Multi-Society Dyslipidemia Guideline introduced significant changes; but, this episode isn't just about what's new. It's about why the field decided a change was necessary in the first place. In the first installment of this four-part CME/CE-accredited series, host Dave Dixon, PharmD, CLS, FNLA sits down with NLA President Dinesh Kalra, MD, FNLA and Salim Virani, MD to unpack the foundational shift from cholesterol-focused care to a broader dyslipidemia paradigm. The conversation covers why atherogenic lipoprotein exposure earlier in life matters, the key clinical misconceptions embedded in the prior guideline, and what clinicians most commonly misunderstand about lipid risk. This episode is a companion piece to the Month 1 webinar, From Cholesterol to Dyslipidemia: What Changed in the 2026 Guideline ? We encourage you to check it out as the two were built to work together: https://youtu.be/9v4WBVfKsho . CME/CE Credit: This activity has been approved for AMA PRA Category 1 Credit and is eligible for ACPE, ANCC, and CDR credit. CME/CE credit is provided by the National Lipid Association. Claim your credit and complete the activity assessment at lipid.org/lipidinsights. Questions? Contact CME@lipid.org .

Hot off the European Society of Cardiology Congress in Munich, this Lipid Insights episode takes a closer look at a significant announcement in triglyceride science and its implications for clinical practice. Host Peter H. Jones, MD, MNLA sits down with Christie M. Ballantyne, MD, MNLA to discuss the 12-month pivotal trial results from SHASTA-3 and SHASTA-4 — evaluating plozasiran in patients with severe hypertriglyceridemia. If you missed Munich, this is your catch-up. Watch the video version on YouTube HERE .

Familial chylomicronemia syndrome (FCS) is one of the rarest and most challenging lipid disorders to manage, but the landscape is changing rapidly. In this Industry Innovations episode, guest host Kevin Maki, PhD, CLS, MNLA sits down with Archna Bajaj, MD, FNLA for a comprehensive and forward-looking conversation on FCS from every angle. Dr. Bajaj walks through the realities of living with FCS — from diagnosis to the demands of a strict ultra-low-fat diet — before turning to what has the field buzzing: two landmark APOC3-targeting therapies and the clinical trial data behind them. A must-listen for any clinician caring for patients with rare lipid disorders, and a glimpse at a future where FCS management looks fundamentally different. This episode's topic comes courtesy of Arrowhead Pharmaceuticals, Inc. a member of the NLA Industry Council. Watch this episode on YouTube HERE .

In this Lipid Insights episode, host Peter H. Jones, MD, MNLA sits down with Thomas Dayspring, MD, FACP, MNLA — widely known as "Dr. Lipid" — for a deep dive into one of lipidology's most complex and frequently misrepresented topics: HDL-Cholesterol. From the history of HDL and how our understanding of it has evolved over decades, to a true microscope-level look at HDL biochemistry and functionality, Dr. Dayspring does what he does best: peeling back the layers to reveal what HDL is really telling us and what it isn't. Follow @drlipid on X (Twitter) and LinkedIn .

How do we move the needle on cardiovascular prevention — not just in the clinic, but across entire systems and communities? In this episode of Lipid Insights, host Alan S. Brown, MD, MHA, MNLA sits down with Nihar R. Desai, MD, MPH, FNLA for a forward-thinking conversation on long-term LDL exposure and what it truly means to practice longevity medicine. From the power of imaging as a patient education tool to the momentum behind the 2026 dyslipidemia guidelines, Dr. Desai shares his vision for a healthcare landscape where patients are empowered, systems are hardwired to deliver better care, and public education closes the gap between what we know and what gets done. A timely and thought-provoking listen for any clinician committed to moving cardiovascular prevention forward.

What does your patient's lipid panel actually tell you and what is it missing? In this special National Lipid Day episode of Lipid Insights, host Peter H. Jones, MD, MNLA, sits down with Thomas Dayspring, MD, FACP, MNLA — widely known as "The Lipid Doctor" — for a conversation that challenges some of medicine's most entrenched assumptions about lipid risk assessment. From the clinical superiority of ApoB over LDL-C and the underrecognized atherogenic burden of Lipoprotein(a), to why HDL-C should no longer be treated as a therapeutic target, Dr. Dayspring delivers evidence-based truths that have direct implications for how clinicians assess and manage cardiovascular risk. If you order lipid panels, counsel patients on cholesterol, or manage ASCVD risk in any capacity — this episode is essential listening. Follow @drlipid on X (Twitter) and LinkedIn. https://x.com/Drlipid https://www.linkedin.com/in/thomas-dayspring-md-facp-fnla-3aaa876/

In this episode of Lipid Insights, host Peter H. Jones, MD, MNLA sits down with Nivedita Patni, MD , of the Department of Pediatrics at UT Southwestern Medical Center in Dallas, TX, to explore the complex landscape of pediatric dyslipidemia. Dr. Patni walks through the critical importance of tailoring management to etiology, the long-term cardiovascular and metabolic risks that hang in the balance, and why early identification is everything. Drawing on case studies and evidence-based management strategies, Dr. Patni shares practical implementation guidelines for clinicians navigating these challenging diagnoses — including the challenges that make rare lipid disorders in children so easy to overlook and so difficult to treat. She also highlights the essential role of multidisciplinary care, bringing together endocrinology, dietetics, and family support to deliver truly individualized treatment. Whether you're seeing these patients regularly or encountering them for the first time, this episode will sharpen your clinical lens and equip you with actionable strategies to make a difference early.

Childhood obesity is one of the most pressing public health challenges of our time — and its long-term cardiovascular and metabolic consequences make it essential territory for lipidologists and clinicians alike. In this episode of Lipid Insights, host Peter H. Jones, MD, MNLA sits down with Casey Berman, MD to explore the full picture: how childhood obesity is defined, why its prevalence continues to rise, and the behavioral, societal, and genetic factors fueling the epidemic. They also dive into associated comorbidities and the latest prevention and management strategies — from lifestyle modifications and pharmacotherapy to the evolving role of bariatric and metabolic surgery. A must-listen for any clinician looking to better support their youngest patients.

Join host Dr. Peter H. Jones for a special episode of Lipid Insights discussing the 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia. Dr. Jones is joined by guideline author and NLA Past President Dr. Joseph Saseen and NLA President-Elect Dr. Dinesh Kalra to break down what clinicians need to know. From the restoration of LDL-C treatment goals and major conceptual shifts from the 2018 guideline, to primordial and primary prevention, risk assessment, special populations, and real-world implementation challenges, this episode covers it all. The panel also explores the guideline's expanded scope beyond LDL-C to include triglycerides, Lp(a), ApoB, and more. This is a must-listen episode for anyone involved in dyslipidemia management. Read the Guidelines here: https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016

In this episode of Lipid Insights, we explore the NLA's recent expert meta-analysis, "Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials." Lead author Dinesh K. Kalra, MD, MBA and key author Kevin C. Maki, PhD, CLS, MNLA join host Alan S. Brown, MD, MHA, MNLA to examine the relationship between LDL-C reduction and major adverse cardiovascular events in primary prevention trials. Together, they break down the findings, clinical implications, and why early LDL-C lowering remains central to preventing first cardiovascular events. Read the meta-analysis: https://www.lipidjournal.com/article/S1933-2874(26)00039-5/fulltext

In this episode of Lipid Insights, host Dr. Peter Jones is joined by renowned experts Robert H. Eckel, MD, FNLA and Samuel M. Kim, MD for a thoughtful discussion on the complex relationship between obesity, weight loss, and cardiometabolic health.

Hosted by Dave Dixon, PharmD, CLS, FNLA, this episode features an in-depth discussion with three key authors of the NLA’s new statement providing updated guidance on diagnosis, management, and treatment of FH. Together, they review the most important updates in the new guidance, including recommendations for earlier identification, the role of genetic testing and cascade screening, updated LDL-cholesterol treatment targets, and the integration of newer lipid-lowering therapies. The conversation also addresses practical considerations for managing FH across the lifespan, from pediatric care to special populations, with a focus on translating evidence-based recommendations into real-world clinical practice. You can watch the video version of this podcast HERE . You can read the official NLA consensus statement published open-access in the Journal of Clinical Lipidology HERE . Podcast listeners can claim credit for listening to the podcast HERE . This podcast has been approved for AMA PRA Category 1 Credit™ . This activity is eligible for ACPE, ANCC, and CDR credit.

Dr. Peter Jones welcomes Dr. Nihar Desai for a forward-looking discussion on the future of cardiovascular prevention. From implementation science to performance measurement, this episode challenges traditional approaches and explores how innovation, systems thinking, and accountability can reshape how we achieve lasting cardiovascular health. Guest: Nihar R. Desai, MD, MPH Associate Professor of Medicine Yale School of Medicine Vice Chief, Section of Cardiovascular Medicine Yale New Haven Health System New Haven, CT Watch the Video

In this episode of Lipid Insights , host Dr. Peter Jones is joined by Dr. Harold Bays for a practical, clinician-focused discussion of the ATTAIN Study and what it means for everyday lipid management. Together, they walk through the key questions clinicians ask when new evidence emerges: what the study set out to evaluate, how to interpret the findings in context, and where the results may (or may not) shift decision-making at the point of care. Dr. Bays brings a real-world lens to the conversation—highlighting how study design, patient selection, endpoints, and background therapy can influence how we apply data in practice. The episode emphasizes translating evidence into action, from identifying the right patients to aligning therapeutic strategy with risk, goals, and adherence realities. Whether you’re looking to sharpen your interpretation of clinical trial data or refine your approach to lipid-related risk reduction, this discussion offers clear takeaways you can use immediately. YouTube Link: https://youtu.be/s65WHd1WjII

Join host Peter Jones, MD, MNLA for a conversation on the evolving landscape of metabolic health in youth. In this episode, Dr. Jones is joined by two leading pediatric experts— Don Wilson, MD, FNLA and Amy Shah, MD, FNLA —to explore practical strategies and emerging research on managing lipids and metabolic syndrome in younger populations. The discussion highlights key findings from their recently published special issue in the Journal of Clinical Lipidology , offering listeners evidence-based insights and clinical pearls to improve outcomes in pediatric and adolescent care. Whether you’re a clinician, researcher, or simply passionate about preventive cardiometabolic health, this episode delivers expert perspectives you won’t want to miss.

Rewriting the Risk Equation: The Expanding Role of Lp(a) in Atherosclerotic Disease Hosted by Dr. Underberg, the Rewriting the Risk Equation: The Expanding Role of Lp(a) in Atherosclerotic Disease podcast is designed to equip clinicians with the latest evidence on Lp(a) biology, screening strategies, and current and emerging therapeutic options. Along with Drs. Soffer, Kulkarni and Wilkinson, they will explore the integration of Lp(a) assessment into routine practice, implications for high-risk populations including those with familial hypercholesterolemia (FH), and strategies to mitigate cardiovascular risk until targeted therapies become available. You can watch a video version of this podcast by Clicking Here

Can genetic scores unlock better outcomes for patients with FH? This special Snippet from our Lipid Insights podcast series dives into the award-winning abstract from #NLASessions 2025, exploring how polygenic risk scores for coronary artery disease may transform ASCVD prediction and management. Tune in and see what’s next in lipid science. Guest Host Daniel E. Soffer, MD, MNLA University of Pennsylvania Health System Internal Medicine/Clinical Lipidology Perelman Center for Advanced Medicine Philadelphia, PA Guest Alexis Baass, MD, MSc, FNLA Alexis Baass, MD, MSc, FNLA Director of the Lipids Nutrition and Cardiovascular Prevention Clinic Montreal Clinical Research Institute Montreal, QC, Canada Click here to see the video version of this episode

In this episode of Lipid Insights, Dr. Peter Jones and guest Dr. Kevin Maki explore whether beef deserves its long-standing reputation as a driver of cardiovascular disease. Drawing on a recent systematic review and meta-analysis, they examine beef’s impact on cholesterol, blood pressure, and other key CVD risk factors—providing fresh perspective for clinicians navigating dietary guidance. This podcast has been approved for AMA PRA Category 1 Credit ™. This activity is eligible for ACPE, ANCC, and CDR credit. To read full accreditation information and claim credit, CLICK HERE .

In this short episode, guest host Dr. Dan Soffer chats with Dr. Joshua Hyman , the Young Investigator Award winner at #NLASessions 2025. Dr. Hyman gives a quick overview of his award-winning abstract and shares insights from his work in advancing lipid research.

Hosted by Dr. Dan Soffer, this conversation brings NLA President Dr. Willard and Beth Jackson together to unpack the Association’s guidance, “LDL Cholesterol Management Simplified in Adults – Lower for Longer is Better.” The trio turns a big message into practical moves: why lifetime LDL exposure matters, who needs more aggressive targets, and how to streamline therapy choices from high-intensity statins to add-ons (ezetimibe, PCSK9-directed options) when goals aren’t met. They share real-world tactics on adherence, stepwise intensification, shared decision-making, and navigating special populations—all in a clear, clinic-ready format. Read the featured article HERE Watch this video on YouTube HERE Guest Host Daniel E. Soffer, MD, MNLA University of Pennsylvania Health System Internal Medicine/Clinical Lipidology Perelman Center for Advanced Medicine Philadelphia, PA Kaye-Eileen Willard, MD, FNLA Medical Director Lipid Clinic Physician Advisor, Ascension SE Wisconsin Chief of Staff Ascension All Saints Chair Joint Chiefs of Staff Ascension SE Wisconsin Racine, WI Beth Jackson, MSN, ACNS-BC, CLS, FNLA Prevention Lipid Clinic App Manager Baylor Scott and White Division of Cardiology Temple, TX